Research programme: PPAR alpha/gamma agonists - BayerAlternative Names: PPAR alpha/gamma activators research programme - Bayer; Research programme: PPAR alpha/gamma activators - Bayer; Research programme: PPAR gamma/alpha activators - Bayer
Latest Information Update: 25 Aug 2003
At a glance
- Originator Bayer
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 25 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Germany (unspecified route)
- 23 Oct 2001 Preclinical development for Type-2 diabetes mellitus in Germany (Unknown route)